Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1049-1056

  McKinsey, David S ^a   Wheat, L Joseph ^b   Cloud, Gretchen A ^c   Pierce, Mark ^d   Black, John R ^e   Bamberger, David M ^f   Goldman, Mitchell ^b   Thomas, Carolynn J ^c   Gutsch, Heidi M ^g   Moskovitz, Bruce ^h   Dismukes, William E ^c   Kauffman, Carol A ^g   Smith, D ^d   Lee, B ^d   Driks, M ^d   Connolly, P ^d   Nixon, H ^d   Ryan, S ^d   Flanagan, C ^d   Richardson, J ^d   McKinsey, J ^d   Norris, S ^d   Slama, T ^d   Yates, R ^d   Baker, B ^d   Fraiz, J ^d   Simpson, D ^d   Larkin, J ^d   Weissinger, B ^d   Baruch, A ^d   Dine, A ^d   Lancaster, D ^d   Ray, D ^d   Threlkeld, M ^d   more..

^a Research Medical Center Brookside Campus   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Box 1734 ^*

^e Infectious Disease of Indianapolis   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; DIDANOSINE; FLUCONAZOLE; ITRACONAZOLE; POLYSACCHARIDE;

ADULT; ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; FUNGUS CULTURE; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL; TREATMENT FAILURE;

EID: 0032938899     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514744     Document Type: Article

References (29)

1. 1. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185-9.
2. 2. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin prophylaxis against disseminated Mycobacterium avium infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-90.
3. 3. Carr A, Tindall B, Brew BJ, et al. Low dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117:106-11.
4. 4. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-8.
5. 5. Powderly W. Fungi. In: Broder S, Merigan TC, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994: 345-57.
6. 6. Wheat J, Goldman M. Antifungal prophylaxis in AIDS: should it be the standard of care? AIDS Clin Care 1994; 6:27-30.
7. 7. Clumek N. Primary prophylaxis against opportunistic infections in patients with AIDS. N Engl J Med 1995; 332:739-40.
8. 8. Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46(RR-12):1-46.
9. 3: demonstration of efficacy in a prospective, multicenter trial. Clin Infect Dis 1996; 23:1282-6.
10. 10. Nightingale SD, Cal SY, Peterson DM. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992; 6:191-4.
11. 11. Powderly W, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:700-5.
12. 12. McKinsey D, Spiegel R, Hutwagner L, et al. Prospective study of histoplasmosis in patients with human immunodeficiency virus infection: incidence, risk factors, and pathophysiology. Clin Infect Dis 1997; 24: 1195-203.
13. 13. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37:310-44.
14. 14. May D, Drew R, Yedinak K, Bartlett J. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacothcrapy 1994; 14:509-13.
15. 15. Bodet CA, Jorgensen JH, Drutz DJ. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol 1985; 22: 157-60.
16. 16. Fromtling RA, Galgiani JN, Pfaller MA, et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 1993; 37:39-45.
17. 17. Rubenstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. Journal of Chronic Disease 1981; 34:469-79.
18. 18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-81.
19. 19. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames, Iowa: Iowa State University Press, 1967.
20. 20. Goldman M, Cloud G, Smedema M, et al. Dues long-term itraconazole prophylaxis result in azole resistance in mucosal Candida albicans isolates from persons with advanced HIV infection? [abstract 531]. Clin Infect Dis 1997; 25:453.
21. 21. Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995; 345:548-52.
22. 22. McKinsey D, Kauffman C, Pappas P, et al. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996; 23:996-1001.
23. 23. Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1997; 103:223-32.
24. 24. Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother 1997; 41:410-4.
25. 25. Cauteren H, Heykants J, Decoster R, Cauwenberg G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987; 9(suppl 1):S47-50.
26. 26. Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2554-8.
27. 27. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27:613-7.
28. 28. Wilcox C, Darouiche R, Laine L, Moskovitz B, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of oral candidiasis. J Infeet Dis 1997; 176:227-32.
29. 29. Dairouche R, Graybill J, Vazquez H, Murray P, Wu J, Moskovitz B. Itraconazole oral solution for the treatment of oropharyngeal candidiasis: results of two randomized blinded studies [abstract MO.B. 116]. In: Program and abstracts of the 11th International Conference on AIDS (Vancouver, British Columbia, Canada). Vancouver: XI International Conference on AIDS Society, 1996.